NasdaqGM:NTLA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Intellia Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NTLA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.1%

NTLA

-4.0%

US Biotechs

-1.4%

US Market


1 Year Return

112.6%

NTLA

31.7%

US Biotechs

17.8%

US Market

Return vs Industry: NTLA exceeded the US Biotechs industry which returned 33.9% over the past year.

Return vs Market: NTLA exceeded the US Market which returned 18.5% over the past year.


Shareholder returns

NTLAIndustryMarket
7 Day-3.1%-4.0%-1.4%
30 Day4.0%0.1%4.7%
90 Day22.7%-3.5%8.2%
1 Year112.6%112.6%34.0%31.7%20.5%17.8%
3 Year-10.9%-10.9%18.7%12.8%42.2%32.7%
5 Yearn/a13.4%5.4%83.4%62.7%

Price Volatility Vs. Market

How volatile is Intellia Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Intellia Therapeutics undervalued compared to its fair value and its price relative to the market?

3.92x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NTLA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NTLA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NTLA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: NTLA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NTLA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NTLA is overvalued based on its PB Ratio (3.9x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Intellia Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

-3.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NTLA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NTLA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NTLA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NTLA's revenue (28.2% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: NTLA's revenue (28.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NTLA is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Intellia Therapeutics performed over the past 5 years?

-36.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NTLA is currently unprofitable.

Growing Profit Margin: NTLA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NTLA is unprofitable, and losses have increased over the past 5 years at a rate of 36.1% per year.

Accelerating Growth: Unable to compare NTLA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NTLA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: NTLA has a negative Return on Equity (-33.02%), as it is currently unprofitable.


Next Steps

Financial Health

How is Intellia Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: NTLA's short term assets ($446.4M) exceed its short term liabilities ($59.1M).

Long Term Liabilities: NTLA's short term assets ($446.4M) exceed its long term liabilities ($80.1M).


Debt to Equity History and Analysis

Debt Level: NTLA is debt free.

Reducing Debt: NTLA has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NTLA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: NTLA has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 42.7% each year.


Next Steps

Dividend

What is Intellia Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NTLA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NTLA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NTLA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NTLA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NTLA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

John Leonard (63 yo)

2.75yrs

Tenure

US$903,786

Compensation

Dr. John M. Leonard, M.D., has been a Director at IQVIA Holdings Inc. since February 2015 and has been its Lead Director since July 25, 2018. Dr. Leonard has been the President and Chief Executive Officer ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD903.79K) is below average for companies of similar size in the US market ($USD4.48M).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
John Leonard
President2.75yrsUS$903.79k0.90%
$ 12.4m
Glenn Goddard
Executive VP & CFO2yrsUS$541.84k0%
$ 0
Andrew Schiermeier
Executive VP & COO1.25yrsUS$1.23m0.018%
$ 242.3k
Laura Sepp-Lorenzino
Executive VP & Chief Scientific Officer1.42yrsUS$1.76m0%
$ 0
José Rivera
Executive VP6.25yrsUS$637.65k0.52%
$ 7.1m
Nessan Bermingham
Founder & Member of Scientific Advisor Boardno dataUS$11.27mno data
Rachel Haurwitz
Co-Founder6.42yrsUS$311.57kno data
Andrew May
Founder and Member of Scientific Advisor Boardno datano datano data
Jennifer Doudna
Founder & Member of Scientific Advisor Board5.5yrsno datano data
Derrick Rossi
Founder & Member of Scientific Advisor Board5.5yrsno datano data
Rodolphe Barrangou
Founder & Member of Scientific Advisor Boardno datano datano data
Luciano Marraffini
Founder & Member of Scientific Advisor Boardno datano datano data

2.8yrs

Average Tenure

52yo

Average Age

Experienced Management: NTLA's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Leonard
President2.75yrsUS$903.79k0.90%
$ 12.4m
Nessan Bermingham
Founder & Member of Scientific Advisor Boardno dataUS$11.27mno data
Andrew May
Founder and Member of Scientific Advisor Boardno datano datano data
Jennifer Doudna
Founder & Member of Scientific Advisor Board5.5yrsno datano data
Derrick Rossi
Founder & Member of Scientific Advisor Board5.5yrsno datano data
Rodolphe Barrangou
Founder & Member of Scientific Advisor Boardno datano datano data
Luciano Marraffini
Founder & Member of Scientific Advisor Boardno datano datano data
Erik Sontheimer
Founder & Member of Scientific Advisor Boardno datano datano data
Jean-Francois Formela
Independent Director6.42yrsUS$179.50k0%
$ 0
Caroline Dorsa
Independent Director4.83yrsUS$234.70k0.0092%
$ 127.1k
Perry Karsen
Independent Director4.5yrsUS$256.50k0.0085%
$ 117.4k
Frank A. G. Verwiel
Independent Chairman of the Board0.67yrUS$225.50k0%
$ 0

5.5yrs

Average Tenure

61yo

Average Age

Experienced Board: NTLA's board of directors are considered experienced (5.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.2%.


Top Shareholders

Company Information

Intellia Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Intellia Therapeutics, Inc.
  • Ticker: NTLA
  • Exchange: NasdaqGM
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.380b
  • Shares outstanding: 58.74m
  • Website: https://www.intelliatx.com

Number of Employees


Location

  • Intellia Therapeutics, Inc.
  • 40 Erie Street
  • Suite 130
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NTLANasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDMay 2016
38IDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2016
0JBULSE (London Stock Exchange)YesCommon StockGBUSDMay 2016

Biography

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRIS ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 01:18
End of Day Share Price2020/10/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.